Skip to main content

Drug Interactions between pegulicianine and Uribel Tabs

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

methylene blue pegulicianine

Applies to: Uribel Tabs (benzoic acid / hyoscyamine / methenamine / methylene blue / phenyl salicylate) and pegulicianine

GENERALLY AVOID: Coadministration with blue and possibly other dyes used for sentinel lymph node (SLN) mapping procedures may reduce the efficacy of pegulicianine imaging. The proposed mechanism is interference with the fluorescent signal from pegulicianine by the dye. Blue dyes have been demonstrated to fluoresce at the same wavelengths as the active metabolites of pegulicianine, which may reduce its capacity to produce the fluorescent signal that is used to differentiate cancerous tissue from normal cells. Concomitant use of any dye for SLN mapping on the day of surgery prior to imaging the lumpectomy cavity was listed in the exclusion criteria in clinical trials evaluating pegulicianine; hence, clinical data are not available.

MANAGEMENT: Administration of dyes for sentinel lymph node (SLN) mapping procedures should generally be avoided prior to imaging the lumpectomy cavity in patients receiving pegulicianine.

References (5)
  1. (2024) "Product Information. Lumisight (pegulicianine)." Lumicell, Inc.
  2. Pellini F, Bertoldi L, deguidi g, et al. (2022) "The use of indocyanine green as the only tracer for the identification of the sentinel lymph node in breast cancer: safety and feasibility." Gland Surg, 11, p. 1139-47
  3. Nagao T, Kinoshita T, Hojo T, Kurihara H, tsuda h (2012) "Sentinel lymph node biopsy using indigo carmine blue dye and the validity of '10% rule' and '4 nodes rule.'" Breast, 21, P455-8
  4. Lumicell, Inc. (2024) Investigation of novel surgical imaging for tumor excision (INSITE). https://clinicaltrials.gov/study/NCT03686215
  5. Smith BL, hunt kk, Carr D, et al. (2024) Intraoperative fluorescence guidance for breast cancer lumpectomy surgery. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200333#ap1

Drug and food interactions

Moderate

hyoscyamine food

Applies to: Uribel Tabs (benzoic acid / hyoscyamine / methenamine / methylene blue / phenyl salicylate)

GENERALLY AVOID: Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system. No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load. However, one study found impairment of attention in subjects given atropine 0.5 mg or glycopyrrolate 1 mg in combination with alcohol.

MANAGEMENT: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.

References (1)
  1. Linnoila M (1973) "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol, 6, p. 107-12

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer